Literature DB >> 19039557

[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.

Hossein Jadvar1, Wei Ye, Susan Groshen, Peter S Conti.   

Abstract

OBJECTIVE: We determined the glucose metabolism and computed tomographic (CT) density of the normal prostate gland in relation to age and prostate size on [F-18] fluorodeoxyglucose positron emission tomography (PET)-CT.
METHODS: We determined the CT density (Hounsfield Units, HU) and glucose metabolism (standardized uptake value, SUV) of the normal prostate in 145 men (age range 22-97 years) on PET-CT scans which were performed for indications unrelated to prostate pathology. Correlations among SUV, HU, prostate size, and age were calculated using Pearson's correlation coefficients, scatter plots, and linear regression trend lines. The SUV and HU values were also compared among different primary cancer types using the Kruskal-Wallis test.
RESULTS: The population average and range of the normal prostate size were 4.3 +/- 0.5 cm (mean +/- SD) and 2.9-5.5 cm, respectively. The population average of mean and maximum CT densities was 36.0 +/- 5.1 HU (range 23-57) and 91.7 +/- 20.1 HU (range 62-211), respectively. The population average of mean and maximum SUV was 1.3 +/- 0.4 (range 0.1-2.7) and 1.6 +/- 0.4 (range 1.1-3.7), respectively. Mean SUV tended to decrease as the prostate size increased (r = -0.16, P = 0.058). Higher mean HU was correlated with higher mean SUV (r = 0.18, P = 0.033). The strongest association was observed between age and prostate size. The prostate gets larger as age increases (r = 0.32, P < 0.001). Prostate mean SUV, max SUV, mean HU, and max HU were not significantly different among different types of primary cancers.
CONCLUSIONS: Although the normal prostate size increases with age, it does not significantly affect the gland's metabolism and CT density, and therefore age-correction of these parameters may be unnecessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039557      PMCID: PMC2636719          DOI: 10.1007/s12149-008-0177-5

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  32 in total

1.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

2.  MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.

Authors:  Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch
Journal:  Nucl Med Biol       Date:  2002-11       Impact factor: 2.408

3.  Dependence of FDG uptake on tumor microenvironment.

Authors:  Andrei Pugachev; Shutian Ruan; Sean Carlin; Steven M Larson; Jose Campa; C Clifton Ling; John L Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

Review 4.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

5.  Glucose metabolism of human prostate cancer mouse xenografts.

Authors:  Hossein Jadvar; Li Xiankui; Antranik Shahinian; Ryan Park; Michel Tohme; Jacek Pinski; Peter S Conti
Journal:  Mol Imaging       Date:  2005 Apr-Jun       Impact factor: 4.488

Review 6.  The roles of PET and PET/CT in the diagnosis and management of prostate cancer.

Authors:  Nobukazu Takahashi; Tomio Inoue; Jin Lee; Takako Yamaguchi; Kazuya Shizukuishi
Journal:  Oncology       Date:  2008-01-07       Impact factor: 2.935

7.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

8.  Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.

Authors:  E C S C Etchebehere; H A Macapinlac; M Gonen; K Humm; H W D Yeung; T Akhurst; H I Scher; S M Larson
Journal:  Q J Nucl Med       Date:  2002-06

9.  Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.

Authors:  J Sung; J I Espiritu; G M Segall; M K Terris
Journal:  BJU Int       Date:  2003-07       Impact factor: 5.588

10.  Age-related structural and metabolic changes in the pelvic reproductive end organs.

Authors:  David Well; Hua Yang; Mohamed Houseni; Sireesha Iruvuri; Saad Alzeair; Maddalena Sansovini; Nancy Wintering; Abass Alavi; Drew A Torigian
Journal:  Semin Nucl Med       Date:  2007-05       Impact factor: 4.446

View more
  11 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

4.  Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?

Authors:  Anne Couture; Mounsif Azizi; Daniel Taussky; Michael McCormack
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

5.  18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.

Authors:  Hakan Öztürk; Inanç Karapolat
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

6.  Clinical significance of incidental FDG uptake in the prostate gland detected by PET/CT.

Authors:  Ertan Sahin; Umut Elboga; Ebuzer Kalender; Mustafa Basıbuyuk; Hasan Deniz Demir; Yusuf Zeki Celen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  PET/CT in prostate cancer: non-choline radiopharmaceuticals.

Authors:  P Castellucci; H Jadvar
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-08       Impact factor: 2.346

Review 8.  Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2010-12-13       Impact factor: 10.057

Review 9.  Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

Review 10.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.